

Summary of Recommendations for Adult Immunization

Adapted from the Advisory Committee on Immunization Practices (ACIP) recommendations by the Immunization Action Coalition, November 2001

Vaccine name and route	For whom it is recommended	Schedule for routine and “catch-up” administration	Contraindications (mild illness is not a contraindication)
Influenza Give IM	<ul style="list-style-type: none"> Adults who are 50yrs of age or older. People 6m–50yrs of age with medical problems such as heart disease, lung disease, diabetes, renal dysfunction, hemoglobinopathies, immunosuppression, and/or people living in chronic care facilities. People (≥6m of age) working or living with at-risk people. Pregnant women who have underlying medical conditions should be vaccinated before influenza season, regardless of the stage of pregnancy. Healthy pregnant women who will be in their 2nd or 3rd trimesters during influenza season. All health care workers and those who provide key community services. Travelers who go to areas where influenza activity exists or who may be among people from areas of the world where there is current influenza activity (e.g., on organized tours). Anyone who wishes to reduce the likelihood of becoming ill with influenza. 	<ul style="list-style-type: none"> Given every year. October through November is the <i>optimal</i> time to receive an annual flu shot to maximize protection. Influenza vaccine may be given at any time during the influenza season (typically December through March) or at other times when the risk of influenza exists. May give with all other vaccines but as a separate injection. 	<ul style="list-style-type: none"> Previous anaphylactic reaction to this vaccine, to any of its components, or to eggs. Moderate or severe acute illness. <p>Note: Pregnancy and breastfeeding are not contraindications to the use of this vaccine.</p>
Pneumococcal polysaccharide (PPV23) Give IM or SC	<ul style="list-style-type: none"> Adults who are 65yrs of age or older. People 2–64yrs of age who have chronic illness or other risk factors, including chronic cardiac or pulmonary diseases, chronic liver disease, alcoholism, diabetes mellitus, CSF leaks, as well as people living in special environments or social settings (including Alaska Natives and certain American Indian populations). Those at highest risk of fatal pneumococcal infection are people with anatomic asplenia, functional asplenia, or sickle cell disease; immunocompromised persons including those with HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure, or nephrotic syndrome; persons receiving immunosuppressive chemotherapy (including corticosteroids); and those who received an organ or bone marrow transplant. Pregnant women with high-risk conditions should be vaccinated if not done previously. 	<ul style="list-style-type: none"> Routinely given as a one-time dose; administer if previous vaccination history is unknown. One-time revaccination is recommended 5yrs later for people at highest risk of fatal pneumococcal infection or rapid antibody loss (e.g., renal disease) and for people ≥65yrs of age if the 1st dose was given prior to age 65 and ≥5yrs have elapsed since previous dose. May give with all other vaccines but as a separate injection. 	<ul style="list-style-type: none"> Previous anaphylactic reaction to this vaccine or to any of its components. Moderate or severe acute illness. <p>Note: Pregnancy and breastfeeding are not contraindications to the use of this vaccine.</p>
Hepatitis B (Hep-B) Give IM Brands may be used interchangeably.	<ul style="list-style-type: none"> All adolescents. High-risk adults, including household contacts and sex partners of HBsAg-positive persons; users of illicit injectable drugs; heterosexuals with more than one sex partner in 6 months; men who have sex with men; people with recently diagnosed STDs; patients receiving hemodialysis and patients with renal disease that may result in dialysis; recipients of certain blood products; health care workers and public safety workers who are exposed to blood; clients and staff of institutions for the developmentally disabled; inmates of long-term correctional facilities; and certain international travelers. <p>Note: Prior serologic testing may be recommended depending on the specific level of risk and/or likelihood of previous exposure. Note: In 1997, the NIH Consensus Development Conference, a panel of national experts, recommended that hepatitis B vaccination be given to all anti-HCV positive persons. Ed. note: Provide serologic screening for immigrants from endemic areas. When HBsAg-positive persons are identified, offer appropriate disease management. In addition, screen their sex partners and household members and, if found susceptible, vaccinate.</p>	<ul style="list-style-type: none"> Three doses are needed on a 0, 1, 6m schedule. Alternative timing options for vaccination include 0, 2, 4m and 0, 1, 4m. There must be 4wks between doses #1 and #2, and 8wks between doses #2 and #3. Overall there must be at least 16wks between doses #1 and #3. Schedule for those who have fallen behind: If the series is delayed between doses, DO NOT start the series over. Continue from where you left off. May give with all other vaccines but as a separate injection. 	<ul style="list-style-type: none"> Previous anaphylactic reaction to this vaccine or to any of its components. Moderate or severe acute illness. <p>Note: Pregnancy and breastfeeding are not contraindications to the use of this vaccine.</p>
Hepatitis A (Hep-A) Give IM Brands may be used interchangeably.	<ul style="list-style-type: none"> People who travel outside of the U.S. (except for Western Europe, New Zealand, Australia, Canada, and Japan). People with chronic liver disease, including people with hepatitis C; people with hepatitis B who have chronic liver disease; illicit drug users; men who have sex with men; people with clotting-factor disorders; people who work with hepatitis A virus in experimental lab settings (not routine medical laboratories); and food handlers when health authorities or private employers determine vaccination to be cost effective. <p>Note: Prevacination testing is likely to be cost effective for persons >40yrs of age as well as for younger persons in certain groups with a high prevalence of hepatitis A virus infection.</p>	<p>For Twinrix™ (hepatitis A and B combination vaccine [GSK]) three doses are needed on a 0, 1, 6m schedule.</p> <ul style="list-style-type: none"> Two doses are needed. The minimum interval between dose #1 and #2 is 6m. If dose #2 is delayed, do not repeat dose #1. Just give dose #2. May give with all other vaccines but as a separate injection. 	<ul style="list-style-type: none"> Previous anaphylactic reaction to this vaccine or to any of its components. Moderate or severe acute illness. Safety during pregnancy has not been determined, so benefits must be weighed against potential risk. <p>Note: Breastfeeding is not a contraindication to the use of this vaccine.</p>

For specific ACIP immunization recommendations refer to the statements, which are published in *MMWR*. To obtain a complete set of ACIP statements, call (800) 232-2522, or to access individual statements, visit CDC’s website: www.cdc.gov/nip/publications/ACIP-list.htm or visit IAC’s website: www.immunize.org/acip

This table is revised yearly due to the changing nature of U.S. immunization recommendations. Visit the Immunization Action Coalition’s website at www.immunize.org/adultrules to make sure you have the most

current version. The Coalition thanks William L. Atkinson, MD, MPH, from CDC’s National Immunization Program, and Linda A. Moyer, RN, and Harold S. Margolis, MD, both from the Division of Viral Hepatitis, at CDC’s National Center for Infectious Diseases, for their review of this table. Responsibility for errors or omissions lies with the editor, Deborah L. Wexler, MD. This table is published by the Immunization Action Coalition, 1573 Selby Avenue, St. Paul, MN 55104. Telephone: (651) 647-9009. E-mail: admin@immunize.org

Summary of Recommendations for Adult Immunization - side 2

Vaccine name and route	For whom it is recommended	Schedule for routine and “catch-up” administration	Contraindications (mild illness is not a contraindication)
Td (Tetanus, diphtheria) Give IM	<ul style="list-style-type: none"> All adolescents and adults. After the primary series has been completed, a booster dose is recommended every 10yrs. Make sure your patients have received a primary series of 3 doses. A booster dose as early as 5yrs later may be needed for the purpose of wound management, so consult ACIP recommendations. 	<ul style="list-style-type: none"> Give booster dose every 10yrs after the primary series has been completed. For those who are unvaccinated or behind, complete the primary series (spaced at 0, 1–2m, 6–12m intervals). Don’t restart the series, no matter how long since the previous dose. May give with all other vaccines but as a separate injection. 	<ul style="list-style-type: none"> Previous anaphylactic or neurologic reaction to this vaccine or to any of its components. Moderate or severe acute illness. <p>Note: Pregnancy and breastfeeding are not contraindications to the use of this vaccine.</p>
MMR (Measles, mumps, rubella) Give SC	<ul style="list-style-type: none"> Adults born in 1957 or later who are ≥18yrs of age (including those born outside the U.S.) should receive at least one dose of MMR if there is no serologic proof of immunity or documentation of a dose given on or after the first birthday. Adults in high-risk groups, such as health care workers, students entering colleges and other post–high school educational institutions, and international travelers, should receive a total of two doses. Adults born before 1957 are usually considered immune but proof of immunity may be desirable for health care workers. All women of childbearing age (i.e., adolescent girls and premenopausal adult women) who do not have acceptable evidence of rubella immunity or vaccination. Special attention should be given to immunizing women born outside the United States in 1957 or later. 	<ul style="list-style-type: none"> One or two doses are needed. If dose #2 is recommended, give it no sooner than 4wks after dose #1. May be given with all other vaccines but as a separate injection. If varicella vaccine and MMR are both needed and are not administered on the same day, space them at least 4wks apart. If a pregnant woman is found to be rubella-susceptible, administer MMR postpartum. 	<ul style="list-style-type: none"> Previous anaphylactic reaction to this vaccine, or to any of its components. Pregnancy or possibility of pregnancy within 4 weeks (use contraception). Persons immunocompromised due to cancer, leukemia, lymphoma, immunosuppressive drug therapy, including high-dose steroids or radiation therapy. Note: HIV positivity is NOT a contraindication to MMR except for those who are severely immunocompromised. If blood products or immune globulin have been administered during the past 11 months, consult the ACIP recommendations regarding time to wait before vaccinating. Moderate or severe acute illness. <p>Note: Breastfeeding is not a contraindication to the use of this vaccine.</p> <p>Note: MMR is not contraindicated if a PPD test was recently applied. If PPD and MMR not given on same day, delay PPD for 4–6wks after MMR.</p>
Varicella (Var) (Chickenpox) Give SC	<p>All susceptible adults and adolescents should be vaccinated. It is especially important to ensure vaccination of the following groups: susceptible persons who have close contact with persons at high risk for serious complications (e.g., health care workers and family contacts of immunocompromised persons) and susceptible persons who are at high risk of exposure (e.g., teachers of young children, day care employees, residents and staff in institutional settings such as colleges and correctional institutions, military personnel, adolescents and adults living with children, non-pregnant women of childbearing age, and international travelers who do not have evidence of immunity).</p> <p>Note: People with reliable histories of chickenpox (such as self or parental report of disease) can be assumed to be immune. For adults who have no reliable history, serologic testing may be cost effective since most adults with a negative or uncertain history of varicella are immune.</p>	<ul style="list-style-type: none"> Two doses are needed. Dose #2 is given 4–8wks after dose #1. May be given with all other vaccines but as a separate injection. If varicella vaccine and MMR are both needed and are not administered on the same day, space them at least 4wks apart. If the second dose is delayed, do not repeat dose #1. Just give dose #2. 	<ul style="list-style-type: none"> Previous anaphylactic reaction to this vaccine or to any of its components. Pregnancy, or possibility of pregnancy within 1 month. Immunocompromised persons due to malignancies and primary or acquired cellular immunodeficiency including HIV/AIDS. (See <i>MMWR</i> 1999, Vol. 28, No. RR-6.) Note: For those on high-dose immunosuppressive therapy, consult ACIP recommendations regarding delay time. If blood products or immune globulin have been administered during the past 5 months, consult the ACIP recommendations regarding time to wait before vaccinating. Moderate or severe acute illness. <p>Note: Breastfeeding is not a contraindication to the use of this vaccine.</p> <p>Note: Manufacturer recommends that salicylates be avoided for 6wks after receiving varicella vaccine because of a theoretical risk of Reye’s syndrome.</p>
Polio (IPV) Give IM or SC	<p>Not routinely recommended for persons 18yrs of age and older.</p> <p>Note: Adults living in the U.S. who never received or completed a primary series of polio vaccine need not be vaccinated unless they intend to travel to areas where exposure to wild-type virus is likely. Previously vaccinated adults can receive one booster dose if traveling to polio endemic areas.</p>	<ul style="list-style-type: none"> Refer to ACIP recommendations regarding unique situations, schedules, and dosing information. May be given with all other vaccines as a separate injection. 	<ul style="list-style-type: none"> Previous anaphylactic or neurologic reaction to this vaccine or to any of its components. Moderate or severe acute illness. <p>Note: Pregnancy and breastfeeding are not contraindications to the use of this vaccine.</p>
Lyme disease Give IM	<ul style="list-style-type: none"> Consider for persons 15–70yrs of age who reside, work, or recreate in areas of high or moderate risk and who engage in activities that result in frequent or prolonged exposure to tick-infested habitat. Persons with a history of previous uncomplicated Lyme disease who are at continued high risk for Lyme disease. (See description in the first bullet.) See ACIP statement for a definition of high and moderate risk. 	<ul style="list-style-type: none"> Three doses are needed. Give at intervals of 0, 1, and 12m. Schedule dose #1 (given in yr 1) and dose #3 (given in yr 2) to be given several weeks before tick season. See ACIP statement for details. If given with other vaccines, give as a separate injection. 	<ul style="list-style-type: none"> Previous anaphylactic reaction to this vaccine or to any of its components. Pregnancy. Moderate or severe acute illness. Persons with treatment-resistant Lyme arthritis. There are not enough data to recommend Lyme disease vaccine to persons with these conditions: immunodeficiency, diseases associated with joint swelling (including rheumatoid arthritis) or diffuse muscular pain, or chronic health conditions due to Lyme disease.
Mening.	Meningococcal disease risk and vaccine availability should be discussed with college students. Give SC. Consult the ACIP statement <i>Meningococcal Disease and College Students</i> (6/30/00) for details.		